Free Trial

scPharmaceuticals (SCPH) Competitors

scPharmaceuticals logo
$5.56 -0.29 (-4.88%)
As of 02:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SCPH vs. ZYME, ORIC, NAGE, MENS, SION, REPL, GHRS, XERS, SNDX, and TRVI

Should you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include Zymeworks (ZYME), Oric Pharmaceuticals (ORIC), Niagen Bioscience (NAGE), Jyong Biotech (MENS), Sionna Therapeutics (SION), Replimune Group (REPL), GH Research (GHRS), Xeris Biopharma (XERS), Syndax Pharmaceuticals (SNDX), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.

scPharmaceuticals vs. Its Competitors

Zymeworks (NYSE:ZYME) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

scPharmaceuticals has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zymeworks$93.38M10.08-$118.67M-$1.49-9.07
scPharmaceuticals$41.98M6.99-$85.15M-$1.91-2.91

In the previous week, Zymeworks and Zymeworks both had 2 articles in the media. scPharmaceuticals' average media sentiment score of 1.75 beat Zymeworks' score of 0.33 indicating that scPharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zymeworks
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
scPharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Zymeworks presently has a consensus target price of $21.00, suggesting a potential upside of 55.38%. scPharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 152.03%. Given scPharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe scPharmaceuticals is more favorable than Zymeworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
scPharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 4.8% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zymeworks has a net margin of -182.75% compared to scPharmaceuticals' net margin of -216.24%. Zymeworks' return on equity of -23.00% beat scPharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Zymeworks-182.75% -23.00% -18.04%
scPharmaceuticals -216.24%-594.07%-73.54%

Zymeworks has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Summary

Zymeworks beats scPharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get scPharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCPH vs. The Competition

MetricscPharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$295.11M$3.04B$5.71B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-2.9321.1328.0720.02
Price / Sales6.99338.95459.47103.02
Price / CashN/A43.2336.5558.97
Price / Book20.578.278.615.88
Net Income-$85.15M-$55.19M$3.24B$258.50M
7 Day Performance12.45%5.50%3.83%2.03%
1 Month Performance39.92%17.25%10.40%12.52%
1 Year Performance11.55%4.61%34.13%19.07%

scPharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCPH
scPharmaceuticals
4.3877 of 5 stars
$5.56
-4.9%
$14.00
+152.0%
+20.7%$295.11M$41.98M-2.9330News Coverage
Positive News
ZYME
Zymeworks
2.9074 of 5 stars
$13.35
+0.1%
$21.00
+57.3%
+34.7%$930.27M$93.38M-8.90460Upcoming Earnings
ORIC
Oric Pharmaceuticals
4.637 of 5 stars
$10.85
-2.3%
$18.57
+71.2%
+8.8%$924.64MN/A-5.8080Positive News
NAGE
Niagen Bioscience
1.5921 of 5 stars
$11.26
-0.4%
$13.22
+17.4%
N/A$886.95M$99.60M66.24120
MENS
Jyong Biotech
N/A$11.61
+16.0%
N/AN/A$882.71MN/A0.0031Quiet Period Expiration
SION
Sionna Therapeutics
N/A$19.94
-2.4%
$38.50
+93.1%
N/A$879.75MN/A0.0035Positive News
Gap Up
REPL
Replimune Group
4.4757 of 5 stars
$11.28
+2.8%
$20.83
+84.7%
-69.8%$869.58MN/A-3.67210Trending News
Analyst Forecast
Analyst Revision
Gap Down
High Trading Volume
GHRS
GH Research
2.1357 of 5 stars
$16.49
+3.9%
$32.00
+94.1%
+22.8%$857.94MN/A-20.8710
XERS
Xeris Biopharma
4.0392 of 5 stars
$5.44
+6.5%
$6.25
+14.9%
+114.5%$850.71M$203.07M-18.13290News Coverage
Positive News
SNDX
Syndax Pharmaceuticals
3.4242 of 5 stars
$9.85
+2.7%
$34.30
+248.2%
-57.5%$847.59M$23.68M-2.55110
TRVI
Trevi Therapeutics
3.8775 of 5 stars
$7.01
+7.0%
$20.88
+197.8%
+164.0%$822.20MN/A-15.5820Positive News

Related Companies and Tools


This page (NASDAQ:SCPH) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners